https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19936 Wed 27 Jul 2022 14:01:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45220 Wed 26 Oct 2022 19:56:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20618 Wed 11 Apr 2018 16:49:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24716 Wed 11 Apr 2018 14:27:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27681 Wed 11 Apr 2018 13:22:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26036 Wed 11 Apr 2018 10:39:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33054 5 % BMD loss after 1 year had triple the percentage increase in MRS FF at 6 months (61.1 % vs. 20.9 %, p = 0.19). Conclusions: Changes are observed on L-spine MRI after 6 months of ADT. Further investigation is warranted of MRS change as a potential predictive biomarker for later BMD loss.]]> Wed 09 Mar 2022 16:02:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48330 Tue 14 Mar 2023 16:54:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12469 Sat 24 Mar 2018 08:16:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12323 Sat 24 Mar 2018 08:11:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17685 Sat 24 Mar 2018 07:57:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20297 cc for OAR and D₁₀₀, D₉₈ and D₉₀ for HR-CTV) were also considered. For patients with small HR-CTV sizes, introduction of MR-based volumetric brachytherapy produced a change in dose delivered to Point A and OAR. Point A doses fell by 4.8 Gy (p = 0.0002) and ICRU and D2cc doses for OAR also reduced (p < 0.01). Mean Point A doses for MR-based brachytherapy treatment plans were closer to those of HR-CTV D₁₀₀ for volumes less than 20 cm³ and HR-CTV D₉₈ for volumes between 20 and 35 cm³, with a significant difference (p < 0.0001) between Point A and HR-CTV D₉₀ doses in these ranges. In order to maintain brachytherapy dose consistency across varying HR-CTV sizes there must be a relationship between the volume of the HR-CTV and the prescription dose. Rather than adopting a ‘one size fits all’ approach during the transition to volume-based prescriptions, this audit has shown that separating prescription volumes into HR-CTV size categories of less than 20 cm³, between 20 and 35 cm³, and more than 35 cm³ the HR-CTV can provide dose uniformity across all volumes and can be directly linked to traditional Point A prescriptions.]]> Sat 24 Mar 2018 07:55:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20180 Sat 24 Mar 2018 07:51:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19994 Sat 24 Mar 2018 07:50:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21027 Sat 24 Mar 2018 07:50:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21552 p > 0.9) were found between CT and pseudo-CT Hounsfield units for organs of interest. Mean ± standard deviation DSC scores for the atlas-based segmentation of the pelvic bones were 0.79 ± 0.12, 0.70 ± 0.14 for the prostate, 0.64 ± 0.16 for the bladder, and 0.63 ± 0.16 for the rectum. Conclusions: The electron-density atlas method provides the ability to automatically define organs and map realistic electron densities to MRI scans for radiotherapy dose planning and DRR generation. This method provides the necessary tools for MRI-alone treatment planning and adaptive MRI-based prostate radiation therapy.]]> Sat 24 Mar 2018 07:50:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38429 p = 0.04, ROC AUC 0.90) and standard deviation (SD) (p = 0.02, ROC AUC 0.90), week 2 skewness (p = 0.02, ROC AUC 0.91) and SD (p = 0.01, ROC AUC 0.94), week 4 kurtosis (p = 0.01, AUC 0.92) and SD (p = 0.01, ROC AUC 0.96). Changes in minimum ADC between baseline and week 2 (p = 0.02, ROC AUC 0.94) and baseline and week 4 (p = 0.02, ROC AUC 0.94) were prognostic for local recurrence. For prediction of any recurrence, ADC minimum (p = 0.02, ROC AUC 0.87) and SD (p = 0.01, ROC AUC 0.85) at baseline, and ADC maximum (p = 0.03, ROC AUC 0.77) and SD (p = 0.02, ROC AUC 0.81) at week 4 were significant. On LASSO logistic regression, ADC minimum and SD at baseline were retained for any recurrence. The only significant finding for DCE-MRI was a correlation of k-trans min at the second follow-up with local recurrence (p = 0.05, AUC 0.84). Conclusion: Several ADC parameters at various time points correlate with recurrence suggesting DW-MRI is a potential biomarker for SCCAC.]]> Fri 10 Sep 2021 12:16:47 AEST ]]>